Back to search

Norway· NO-ID_6D9A6D7F-9F07-468F-A06B-81F36D2B1435

Ruxolitinib Advanz Pharma

A ruxolitinib product containing ruxolitinib, registered in Norway by Advanz Pharma Limited. The same ATC class is registered in 14 of our 19 countries.

ATC L01EJ01

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedRuxolitinib Advanz PharmaATCL01EJ01REGISTER NO.NO-ID_6D9A6D7F-9F07-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Ruxolitinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EJ01 (ruxolitinib), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 8 of them publish a price we can compare per daily dose

Ruxolitinib · ATC L01EJ01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ruxolitinib costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ruxolitinib · price per daily dose (30 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$223.34
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Ruxolitinib
Manufacturer
Advanz Pharma Limited
Country
Norway (NO)
ATC code
L01EJ01
ATC class
Ruxolitinib
Defined daily dose
30 mg, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • gtin
    5060064174227
  • no_merkevare_id
    ID_6D9A6D7F-9F07-468F-A06B-81F36D2B1435
  • no_varenummer
    441032
    56
    NOK 44447.9

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

350 interactions on record for ruxolitinib.

Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ruxolitinib · interactions on record

350 records

  • 92 severe
  • 199 moderate
  • 59 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Polink, Ruxib
  • Bulgaria · Руджави, Руксолитиниб Сандоз
  • Cyprus · Ruxolitinib Sandoz
  • Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
  • Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
  • Estonia · Ruxolitinib Msn
  • Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
  • Finland · Ruxolitinib Orion
  • France · Ruxolitinib Biogaran, Ruxolitinib Olpha
  • United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
  • Greece · Jakulya
  • Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
  • Hungary · Ruxolitinib Sandoz
  • Iceland · Jakavi, Jakulya
  • Italy · Ruxolitinib Vivanta
  • Liechtenstein · Jakavi, Opzelura
  • Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
  • Latvia · Ruxolitinib Msn
  • Malta · Donlize, Ruxolitinib Medichem
  • Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
  • Romania · Ruxolitinib Msn
  • Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f6746b53-de6f-4b98-bf69-fa6251c3efbe
GET /v1/drugs/f6746b53-de6f-4b98-bf69-fa6251c3efbe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablett",
  "source": "fest",
  "status": "A",
  "atc_name": "Ruksolitinib",
  "merkevare_id": "ID_6D9A6D7F-9F07-468F-A06B-81F36D2B1435",
  "name_form_strength": "Ruxolitinib Advanz Pharma tab 20 mg",
  "prescription_group": "C"
}

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.